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ILD during Erlotinib
and Gefitinib
Treatment in Japanese
Patients with Non-
small Cell Lung Cancer
To the Editor:
Hotta et al. compared the inci-
dence and pattern of interstitial lung
disease (ILD) in Japanese patients with
non-small cell lung cancer receiving
treatment with epidermal growth factor
receptor (EGFR) tyrosine kinase inhibi-
tors (TKIs). Two different cohorts of
patients were compared: unselected pa-
tients treated with gefitinib between
2000 and 2003 and selected patients
with a lower proportion of known risk
factors for ILD treated with erlotinib in
2008.1 This article highlights the impor-
tance of appropriate patient selection to
minimize the risk of ILD with EGFR
TKIs: indeed, the authors concluded that
patient selection, because of recent
awareness of risk factors for ILD, may
explain their numerical difference in
ILD incidence between the two EGFR
TKIs in these different time frames. We
found the article interesting and were
encouraged to note that the authors ac-
knowledge numerous limitations in their
comparison. We would also like to point
out that Table 1 incorrectly stated that
8% of patients (rather than the correct
38% of patients) who were treated with
gefitinib had a poor performance status,
an independent risk factor for ILD, com-
pared with 20% of those who were
treated with erlotinib.
In 2002, AstraZeneca, the manu-
facturer of gefitinib, added ILD to the
list of known adverse reactions in the
prescribing information.2 Subsequently,
a large epidemiological study in Japa-
nese patients with non-small cell lung
cancer, designed and conducted by an
independent academic team together
with scientists from AstraZeneca, iden-
tified a number of risk factors for devel-
oping ILD (irrespective of whether the
patient received gefitinib or chemother-
apy).3 AstraZeneca added these risk fac-
tors to the prescribing information2 for
gefitinib in 2006 to provide this impor-
tant information to prescribers as a part
of proactive risk mitigation. The pre-
scribing information for gefitinib has
since been refined and updated several
times to enable clinicians and patients to
make informed prescribing choices: the
warning on this event expanded with
risk factors for mortality associated with
ILD, and frequency of ILD updated to
1.3% (based on the phase III clinical
program).2 This labeling has resulted in
increased awareness and appropriate pa-
tient selection, which is reflected by the
reduction in reporting rates of ILD with
EGFR TKIs. For gefitinib, the reported
incidence rate of ILD in Japan has re-
duced from 5.8% in 2003–20044 to the
current incidence rate of 1.28% (0.64%
in regions outside Japan) (AstraZeneca,
data on file).
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TABLE 1. Summary of the Studies Analyzing ERCC1 Expression in SCLC
Reference Cases Series Method Cutoff Results
Lee et al.4 77 (40 LD/37 ED) IHC (clone 8F1) 10% with 2 Overall, high ERCC1 expression in 17%. No association with
response to CT. High ERCC1 expression significantly
correlated with poor overall survival, particularly in LD.
Ceppi et al.5 85 (45 LD/40 ED) rt-PCR Median (5.3) High ERCC1 expression in 51%. Overall, no correlation with
survival and response to platinumVP16. Patients with LD
and low ERCC1 levels had significantly longer survival. In
LD, low ERCC1 expression is an independent prognostic
factor.
Kim et al.3 130 (18 LD/112 ED) IHC (clone 8F1) 10% ERCC1 expression in 27%. No correlation with survival and
response to platinum-based CT.
Skov et al.1 186 (63 LD/116 ED) IHC (clone 8F1) Positive/negative Positivity in 10% of SCLC. No significant association with
survival was observed. ERCC1 positive carcinoids had longer
survival that the negative ones.
Chiappori et al.2 100 (unknown stage) AQUA Not available Low expression levels when compared with RRM1 and
topoisomerase2alpha
This study 105 (33 LD/72 ED) IHC (clone 8F1) 10% with 2 Overall, ERCC1 expression in 46 cases (43.8%). ERCC1-
negative tumors had a significant correlation with LD and
better survival. ERCC1 expression did not significantly
correlated with response to first-line platinum-based CT.
ERCC1, excision repair cross complementing-1; SCLC, small cell lung cancer; LD, limited disease; ED, extensive disease; rt-PCR, real-time polymerase chain reaction; IHC,
immunohistochemistry; AQUA, immunofluorescence combined with automated quantitative analysis; CT, chemotherapy.
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In Response:
Thank you for the special atten-
tion on our article. Yes, in our article,
we wanted to simply stress the impor-
tance of appropriate patient selection to
minimize the risk of interstitial lung dis-
ease (ILD) with epidermal growth factor
receptor tyrosine kinase inhibitor rather
than the difference itself in the incidence
of ILD with both agents. Indeed, one can
also obtain the similar observation in a
previous Japanese study.1 This shows
that the incidence of ILD has decreased
over years in the gefitinib treatment for
Japanese cohort with 3.0 and 1.4% in
2002 and 2008, respectively.
We sincerely apologize for the in-
correct description of the proportion of
poor performance status patients treated
with gefitinib monotherapy, as Dr. Jones
and colleagues suggested. We, medical
oncologists, truly applaud the great ef-
forts of AstraZeneca company and thank
for the refined and updated proscribing
information for gefitinib. Thanks to this,
we can now properly make the appropriate
patient selection and can obtain the ex-
cellent data showing the safety and ef-
fectiveness of gefitinib monotherapy in
the first-line setting in the selected pa-
tient population.2
Katsuyuki Hotta, MD, PhD
Nagio Takigawa, MD, PhD
Katsuyuki Kiura, MD, PhD
Department of Respiratory Medicine
Okayama University Hospital
Okayama, Japan
REFERENCES
1. Goto K, Kenmotsu H, Nishiwaki Y, et al.
Current trend in incidence of severe interstitial
lung disease (ILD) due to gefitinib in Japan.
Proc Am Soc Clin Oncol 2009;27(Suppl):
Abstr e19075.
2. Maemondo M, Inoue A, Kobayashi K, et al;
North-East Japan Study Group. Gefitinib or
chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med 2010;362:
2380–2388.
Disclosure: The authors declare no conflicts of
interest.
Address for correspondence: Katsuyuki Hotta,
MD, PhD, Department of Respiratory Med-
icine, Okayama University Hospital, 2-5-1,
Shikata-cho, Okayama 700-8558, Japan. E-mail:
khotta@md.okayama-u.ac.jp
Copyright © 2010 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/10/0511-1878
Letters to the Editor Journal of Thoracic Oncology • Volume 5, Number 11, November 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1878
